Proteinics study: Relevance and interest for screening, follow‐up, etiopathogenesis of AMD

Abstract

PurposeTo evaluate Proteinics study impact on AMD diagnosis, screening, follow‐up, etiopathogenesis.MethodsAMD: 40 patients,16 men,24 women,30 with AMD.4 Groups A,B,C,T. A:10 first stage AMD patients,B:10 Atrophy AMD patients(predominant atrophic areas),C:10 patients with Neovascular AMD,T:10 normal patients,control group. Ophthalmologic exam included ETDRS visual acuity(VA),complete ophthalmic examination,Fundus examination,autofluorescence imaging(FAF),(RegionFinderSoftware),optical coherence tomography(HRA Spectral Domain OCT)(OCTenFace software, M‐S software),Fluorescein angiography(FA)and ICG when Neovascular complication. Proteinics Study: Blood tests and analysis, proteinics qualitative and quantitative analysis,all the same for all patients,whatever group. Blood test is done during ophthalmologic exam. Plasma congelation,then Elisa technic,3 stages(SimpleStep Elisa kits)for detection and quantification of IL1β,IL6,IL10,TNFα,tau protein. Classic Elisa technic,2stages,for Amyloid peptid Aß1‐40.Each sample quadruplicate; MicroBCA analysis.ResultsAnalysis will determine proteinics quantitative values in each group of patients, and proportion, characterization, singularity of each of them: group A and C:similar results, higher for C; group T and B:similar results, lower for B. So, characterization, prevalence, specifics of and for each group, therefore a proteinics profile. Proteinics study'evaluation, identification, classification in AMD patients, and especially A, B, C groups allow AMD screening, follow‐up, particularly according to AMD type and stage. Proteinics study may have biomarker feature and let AMD preventionConclusionsProteinics study enhance AMD characterization, allow better diagnosis, follow‐up, screening. Interrelations, correlations between AMD and Proteinics lead to better etiopathogenesis understanding and therapeutics prospects.